Cholangiocarcinoma Foundation Hails Milestone in Effort to Advance new Treatment for IDH1-positive Cholangiocarcinoma Patients as Agios Announces New FDA Filing for TIBSOVO®
“This is an important milestone for this community and specifically for patients with an IDH1 mutation.”
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed